Medically reviewed by Mark Strehlow, MD, Medical Director — November 2026
PT-141 is another name for bremelanotide, a man-made peptide that the FDA has approved only as Vyleesi, for one use, low sexual desire with distress about it in premenopausal women, and that is promoted online far more widely, as a libido and erection aid for women and men. Tested in people: in two randomized trials of 1,267 premenopausal women, the approved injection was shown to improve desire and distress scores by a margin over placebo that the FDA called “modest”, while the number of satisfying sexual events did not rise and 40% of the women on the drug had nausea. The evidence stops there: for men, what remains in good standing is short laboratory studies of erections and one uncontrolled clinic series, and the compounded and “research use only” products sold as PT-141 have not been studied in people.
This review of the evidence, the doses tested and the risks is part of our peptide library. Our providers prescribe some of the peptides reviewed in this library, and we earn money from that care.
At a glance
- FDA status
- Approved as Vyleesi for one use in premenopausal women. Compounded bremelanotide, often sold as PT-141, is not FDA-approved.
- Tested in people
- Two randomized trials of the approved product, 1,267 women: desire and distress improved modestly over placebo. Nausea in 40%.
- The claim you’ve heard
- Works for men too: only laboratory studies of erections and one uncontrolled clinic series; compounded products not studied.
- Doses tested in people
- The approved dose is 1.75 mg under the skin, as needed. No oral or under-the-tongue dose has been tested.
- Sport
- Not named on WADA’s 2026 or 2027 Prohibited List. Tested athletes should confirm with their anti-doping organization.
What PT-141 is
Bremelanotide is a synthetic peptide: seven amino acids joined in a ring. It is a melanocortin receptor agonist, meaning it activates the receptors of a natural hormone, alpha-melanocyte-stimulating hormone. PT-141 is the name it carried in its developer’s early studies.
It is closely related to melanotan II, a peptide with no US approval that is used, unregulated, mainly for tanning. The two have the same ring of amino acids and differ at one end. Whether reports about melanotan II carry over to bremelanotide is unknown.
Three kinds of product go by these names:
- Vyleesi, the FDA-approved product: an autoinjector holding 1.75 mg of bremelanotide in 0.3 mL, injected under the skin.
- Compounded bremelanotide, prepared by a pharmacy for one patient’s prescription. It is not FDA-approved and is not the product the trials tested.
- “Research use only” PT-141, sold online. The FDA calls such products unapproved new drugs.
The developer also tested a nasal spray and then dropped it. No form taken by mouth or under the tongue has been tested in people.
Where it stands with the FDA
Status checked: November 19, 2026.
In plain words: only one bremelanotide product, Vyleesi, is FDA-approved, for low sexual desire with distress about it (HSDD) in women before menopause; compounded bremelanotide, often sold as PT-141, is not. Federal law makes bremelanotide eligible for compounding for one patient’s prescription, but a pharmacy may not make what is essentially a copy of Vyleesi “regularly or in inordinate amounts” unless the prescriber decides that a change made for that patient makes a significant difference for that patient.
Bremelanotide is FDA-approved as Vyleesi, a 1.75 mg autoinjector “indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)”; its label says it “is not indicated for the treatment of HSDD in postmenopausal women or in men.” Compounded bremelanotide, often sold as PT-141, is not FDA-approved. Because bremelanotide is a component of an approved drug, it is eligible for use in compounding under section 503A of federal law for an individual patient’s prescription, but a pharmacy may not compound “regularly or in inordinate amounts” a product that is essentially a copy of Vyleesi, unless the prescriber determines that a change made for that patient “produces for that patient a significant difference”. (As of November 19, 2026.)
The approved product
The FDA approved Vyleesi on June 21, 2019, and its current label took effect on November 5, 2026. The label adds: “VYLEESI is not indicated to enhance sexual performance.” Vyleesi is not indicated in men; compounded bremelanotide is not FDA-approved for any use.
The limit on compounded copies
Vyleesi is marketed today as a prescription medicine and is not on the FDA’s drug-shortage list, so it is “commercially available” in the FDA’s terms. The FDA’s guidance says it “intends to consider” a compounded product essentially a copy when it has the same active ingredient, “the same, similar, or an easily substitutable dosage strength” (similar means within 10%) and the same route; Vyleesi is 1.75 mg, injected under the skin. The exception is a change “made for an identified individual patient, which produces, for that patient, a significant difference”, determined by the prescriber and “documented on the prescription”. The guidance adds: “Other factors, such as a lower price, are not sufficient”.
Kansas
The Kansas rule for sterile preparations, which include injections, is stricter (K.A.R. 68-13-4(n)): “A pharmacist shall not compound a sterile preparation that is essentially a copy.” Kansas counts as a copy any preparation “comparable in active ingredients to a commercially available drug product”; its exceptions are a change that “produces a clinically significant difference for the patient, as determined by the prescribing practitioner”, or a drug on the shortage list. It has no “regularly or in inordinate amounts” allowance, and it reaches preparations shipped into Kansas. The Kansas Board of Pharmacy has published nothing on how it applies the rule to bremelanotide.
HHS’s draft peptide policy
The draft interim policy on peptide compounding that HHS (the federal department the FDA belongs to) announced on October 30, 2026 does not reach bremelanotide: its scope is a substance “that is not a component of an FDA-approved drug product”.
“Research use only” products
Five FDA warning letters to online sellers, dated August 24, 2026, name PT-141 and call such products “unapproved new drugs”. One says: “These products are especially concerning from a public health perspective because injectable drug products can pose risks of serious harm to users.”
Sport
Bremelanotide is not named on WADA’s 2026 Prohibited List or on the 2027 List. The List’s catch-all class covers a substance “with no current approval by any governmental regulatory health authority for human therapeutic use”, and bremelanotide has an FDA approval. That is our reading of the wording, not a ruling from WADA: a tested athlete should confirm with their anti-doping organization.
Claims you’ll see, and why sources disagree
Pages about PT-141 disagree for three reasons:
- They mix up the products. The trial results belong to Vyleesi, used as needed by premenopausal women with HSDD. Pages apply them to men, to compounded products, to products sold online and to nasal sprays, none of which was in those trials.
- They count different outcomes. The desire and distress scores the published trials lead with improved; satisfying sexual events did not. An independent re-analysis (Spielmans and Ellefson, 2024) reported that 8 of 11 registered efficacy outcomes had gone unpublished, with effect sizes that “ranged from nil to small”.
- They read laboratory results as results at home. In men, doses given in a laboratory produced erections on a monitor. The only large at-home trial is under an Expression of Concern.
Where this review says “not tested in people”, that is not the same as “doesn’t work”. It cuts both ways: not shown to help, and not shown to be safe.
| Claim | Level of evidence | Verdict |
|---|---|---|
| Raises desire in premenopausal women with HSDD | Tested in people: two randomized trials | Supported, modestly. Satisfying sexual events did not increase. |
| Works for men, including when pills such as Viagra haven’t | Tested in people: laboratory studies; reported in people: one clinic series | Weakly supported for erections; no at-home trial in good standing. Desire in men: not tested. |
| Consistently positive in men with low libido and in women after menopause; works for women whom other treatments haven’t helped | Not tested in a published trial | No evidence. The FDA: “The efficacy of BMT [bremelanotide] has not been established in postmenopausal women.” |
| Works in 30 to 60 minutes and lasts 24 to 72 hours | Tested in people: onset, and up to 24 hours in one small study | Onset supported. No data behind 72 hours. |
| Heightens sensitivity, pleasure and orgasm, or lifts mood | Not tested as efficacy outcomes | No evidence. The phase 3 trials measured desire and distress and excluded women with depression. A composite sexual-function score rose in the phase 2b trial (+3.6 against +1.9 on placebo). |
| Lowers blood pressure and raises heart rate | Tested in people | Contradicted. It raises blood pressure and lowers heart rate for some hours. |
| Can be taken as a nasal spray | Tested in people, then abandoned | Blood levels varied widely (a coefficient of variation of 179% in an FDA table), and the developer moved to injection. No data on the sprays sold today. |
What the evidence consists of
Nearly all of the trials, and most of the animal work, were run or funded by the drug’s developers, Palatin Technologies and its licensee AMAG Pharmaceuticals, or their paid collaborators. That is a reason for care, so the FDA’s own review and two independent re-analyses are given below as well. No figure below belongs to a compounded or “research use only” product: those have not been studied in people. A sponsor-authored safety review counts 3,500 people in 43 completed studies. Several older studies could be read only as abstracts.
Tested in people: women
| Study | People | Design | What happened | Funding or limits |
|---|---|---|---|---|
| RECONNECT, two phase 3 trials (Kingsberg, 2019) | 1,267 premenopausal women with HSDD | Randomized; the approved injection or placebo, as needed, for 24 weeks | Desire and distress scores improved more than on placebo; satisfying sexual events did not | Sponsored by Palatin. About 4 in 10 on the drug left early. |
| Phase 2b trial (Clayton, 2016) | 397 premenopausal women with arousal disorder, HSDD or both; 327 analysed | Randomized; three dose levels or placebo for 12 weeks | Satisfying sexual events a month: +0.7 against +0.2 on placebo (two higher doses pooled) | Funded by Palatin. Mixed diagnoses. |
| Brain-imaging study (Thurston, 2022) | 40 premenopausal women with HSDD; 31 completed | Randomized crossover; one dose or placebo | More desire “for up to 24 hours”; changed brain responses to erotic images | Investigator-sponsored; part-funded by AMAG. Small. |
An earlier randomized crossover study of one nasal dose in 18 women with arousal disorder (Diamond, 2006; Palatin authors) found more women reporting moderate or high desire, while vaginal vasocongestion “did not change significantly”.
How large the effect was. In the phase 3 trials the desire score runs from 1.2 to 6.0. Against placebo it improved by 0.30 points in one trial and 0.42 in the other (P<.001 in both); the label gives a median change of 0.6 on Vyleesi against 0 on placebo. The distress score, which runs from 0 to 4, improved by 0.37 and 0.29 points more than on placebo. The reported effect sizes were 0.39 for desire and 0.27 for distress. Satisfying sexual events did not differ (a change of 0.0 against −0.1; P=.630). On a question about perceived benefit, 58.3% and 58.2% of women on the drug counted as responders, against 36.1% and 35.4% on placebo.
How the FDA read it. The FDA’s review concluded that bremelanotide “leads to modest improvements in low sexual desire and associated distress” and “did not improve the number of SSEs [satisfying sexual events]”, which it does not require of drugs for HSDD. Its staff set the smallest change in the desire score that matters to a patient at 1.2 points, twice the 0.6 the sponsor proposed and twice the median change in the trials. An FDA staff draft of label wording, not carried into the approved label, put responders at 34 to 36% on Vyleesi against 22% on placebo for desire, and at 51 to 56% against 36 to 42% for distress. The FDA’s conclusion: “We conclude that the benefits of BMT outweigh its risks when used according to labeling.”
What limits the trials. More women left the drug group than the placebo group (41.9% against 16.0% in one trial, 43.8% against 28.4% in the other), and 18% stopped because of adverse reactions, against 2%; missing results were filled in by carrying each woman’s last score forward. The women were 85.6% white and nearly all at US sites; women with depression or taking antidepressants were excluded. The FDA noted that asking about the past month, for a drug taken as needed, biases the result “towards the null”, that is, toward showing less effect.
Other readings of the same data. An independent re-analysis of the FDA application data (Spielmans, 2021) reported that “72.72% of protocol-listed outcomes were not reported” and that, judged by finishing the trial and entering its extension, participants “preferred placebo”; the trial authors replied in a commentary we have not read. A sponsor-authored analysis reports benefit “across all age, weight, and BMI subgroups”, “with few exceptions”. We read both as abstracts.
Tested in people: men
Three randomized placebo-controlled studies by the developer’s researchers gave doses in a laboratory and measured erections on a monitor. By nasal spray (Diamond, 2004) and under the skin (Rosen, 2004), the response exceeded placebo, at the higher doses where a range was tested, in healthy men and in men with erectile dysfunction, including men with an “inadequate response to Viagra”; neither abstract gives the number of men or of doses each man had. In 19 men with erectile dysfunction (Diamond, 2005), one nasal dose with sildenafil produced more response than sildenafil alone, with no new adverse events.
The one large at-home trial (Safarinejad and Hosseini, 2008; 342 men not helped by sildenafil) reported positive results in 33.5% against 8.5% on placebo. It has been under an Expression of Concern since 2023, the same first author’s 2008 trial in women was retracted, and we do not rely on it.
No trial in men measured desire. The FDA’s review says the development programme for erectile dysfunction “did not lead to approved products”; the phase 2b paper says its blood-pressure monitoring was “to address US FDA concerns expressed after earlier studies of an intranasal BMT formulation”.
Tested in people: weight
Two short randomized studies by the developer in a research facility (Spana, 2022): 58 women with obesity given three injections a day lost 1.3 kg more than on placebo in 15 days (interval 0.8 to 1.9 kg); in a 4-day study that 15 of 27 women completed, two a day gave 1.7 kg against 0.9 kg and one a day was not significant.
Reported in people
With no comparison group, the 52-week open-label extension of the phase 3 trials (Simon, 2019) can’t separate the drug from everything else: 684 women entered and 272 completed, and desire scores were 1.25 to 1.30 points above baseline in women who stayed on the drug. The authors note “selection bias” and that “nonresponders are likely underrepresented”.
In men, a published conference abstract from one clinic (Goldstein and Goldstein, 2024) describes the approved product prescribed off-label, with no comparison group and no dose stated: 21 men consented, 19 answered questionnaires, 12 were interviewed, and 53% rated their sexual function at least “a little better” on one questionnaire. Side effects included flushing and nausea (36% each) and “bothersome spontaneous erections without sexual stimulation for about 24 hours after injection” (27%); the abstract does not give the number of men behind any of its percentages. Palatin funded it; its authors call the study investigator-initiated and declare ties to the company.
Animal studies
In female rats (a Palatin-funded study) bremelanotide “selectively increased measures of solicitation”, an approach behaviour that stands in for desire and does not measure it; in female hamsters (independent, NIH-funded) “bremelanotide treatment failed to enhance sexual reward”. In dogs, an independent study of doses by mouth “indicated minimal oral absorption”.
Lab studies and how it is thought to work
The label states: “The mechanism by which VYLEESI improves HSDD in women is unknown.” What is known:
- Receptors (lab studies, in the label). Bremelanotide activates several melanocortin receptors; “At therapeutic dose levels, binding to MC1R and MC4R is most relevant.”
- MC1R, on pigment cells (tested in people). The label says “binding at this receptor leads to melanin expression and increased pigmentation”, which fits the skin darkening seen in trials.
- MC4R, in the brain (tested in people in one small study; animal studies). A single dose changed how brain regions responded to erotic images. Animal studies suggest it acts in the hypothalamus, possibly by releasing dopamine, an account from a review co-authored by Palatin staff. Nausea and lower food intake in people are attributed to MC4R too.
Dosing: what has been tested, what is used, and what the reasoning supports
This section reports what the label states, what the studies gave (none used a compounded or “research use only” product) and what circulates; it recommends nothing. Only one published trial of treatment compared doses, in premenopausal women; for men, after menopause and for other forms, no dose can be called optimal.
Doses tested in people
| Study | People | Dose | Route | How often and how long |
|---|---|---|---|---|
| Vyleesi label (the approved dose) | Premenopausal women with HSDD | 1.75 mg | Under the skin | As needed, “at least 45 minutes before anticipated sexual activity”; “Do not administer more than one dose within 24 hours”; “More than 8 doses per month is not recommended” |
| RECONNECT phase 3 and extension | Premenopausal women with HSDD | 1.75 mg | Under the skin | As needed, up to 12 in 4 weeks; 24 weeks, then a 52-week extension |
| Phase 2b dose-finding (Clayton, 2016) | Premenopausal women with arousal disorder, HSDD or both | 0.75, 1.25 or 1.75 mg | Under the skin | As desired, up to 16 in 4 weeks; 12 weeks |
| Rosen, 2004 | Healthy men; men with erectile dysfunction | 0.3 to 10 mg (the abstract lists no dose levels); 4 or 6 mg | Under the skin | In a laboratory; doses per man not in the abstract |
| Obesity studies (Spana, 2022) | Women with obesity | Daily totals of 2.5 to 6.5 mg in one to three injections; the approved dose is a single 1.75 mg | Under the skin | 15 days in one study; 4 days per period in the other |
| Diamond, 2004 and 2005 | Men with and without erectile dysfunction | 2004: range not in the abstract, effect above 7 mg. 2005: 7.5 mg, with sildenafil 25 mg | Nasal spray | In a laboratory. 2004: doses per man not in the abstract; 2005: one dose per arm |
The dose-finding trial reported: “Effective dosing with 1.25 and 1.75 mg was established. The dose of 0.75 mg did not differ from placebo (ineffective dose).” Other studies gave volunteers and small groups of women single doses of 1.75 to 5.25 mg under the skin or 5 to 20 mg by nasal spray. No dose has been tested in people by mouth, under the tongue or as a troche, or in the nasal sprays sold today; none in a published treatment trial after menopause; none in an at-home trial in men in good standing.
Doses in common use
These amounts circulate as practice that no trial set. Every page with a number for injection also has the label’s 1.75 mg, and most pages repeat its two frequency limits; several give no amount of their own.
- By injection, a band of 1 to 2 mg (telehealth articles, a protocol page, a “research” vendor’s help article): 0.5 or 1 mg as a first dose and 2 mg as a top, with “1.75 mg-2.5 mg as needed” on one clinic handout. No trial of treatment was found for 0.5, 1, 1.5, 2 or 2.5 mg as needed.
- The same amounts for men (the same kinds of page): “1.5 to 2 mg subQ” from a start of “0.5 to 1 mg”, or “1.75 to 2.0 mg”. No page cites a traceable study of them in men; the one study under the skin in men with erectile dysfunction gave 4 or 6 mg, in a laboratory.
- Frequencies past the label’s 8 a month: “2–3 times per week” (a “research” vendor’s help article) and “3-4 times per week” (a telehealth seller’s article on use in men), neither mentioning that figure; “once every 48 hours”, about 15 doses a month (a physician-reviewed telehealth article), printed beside the label’s figure and not reconciled with it.
- Other forms, as strengths rather than doses (pharmacy, telehealth and protocol pages): nasal sprays of 10 and 20 mg/mL, the amount per use given in sprays or not at all; tablets and troches under the tongue holding 1 or 2 mg, always with oxytocin and usually tadalafil, combinations with no study found; “about 8 mg” by nose on one site, its own conversion.
What the pharmacology supports, and what it doesn’t
- Amount. Measured in people: peak blood levels plateau at 7.5 mg under the skin. Inferred: that describes blood levels, not effect, and sets no amount for anyone.
- Frequency. Convention, from the label: its limit of one dose in 24 hours (doses close together “may increase the risk of additive effects on blood pressure”) and its advice against more than 8 a month (few trial patients used more, and more frequent dosing adds skin darkening and time with raised blood pressure). Inferred: both are ceilings for the approved injection, not a schedule.
- Route. Measured in people: under the skin, blood levels peak at about 1 hour, about 100% is absorbed, the half-life is about 2.7 hours, and 4 days of once- or twice-daily dosing in an obesity study caused no build-up; from the developer’s nasal spray they varied widely between people. Inferred: a compounded spray would be expected to deliver unpredictable amounts. Not measured in people: anything by mouth or under the tongue.
- Duration. Claimed and not confirmed: 72 hours; the label says “The duration of efficacy after each dose is unknown”.
- Monitoring. Convention, from the label: it tells prescribers to “ensure blood pressure is well-controlled”, to advise contraception and to stop after 8 weeks without improvement.
What nobody knows: what amount, if any, helps men at home or women after menopause, and whether a compounded or online product holds what its label says.
What common protocols get wrong
- The injection’s label put on other forms. Pharmacy and telehealth product pages carry its indication, frequency limits or trials over to a nasal spray, a troche or tablets under the tongue. No label covers those forms, though each page prints that its product, or that use, is not FDA-approved.
- Trials in women cited for men. A telehealth guide gives the women’s phase 3 trials as its source for studies in men, through links that lead to unrelated papers; a telehealth seller’s article on use in men cites a 52-week extension when the only one found enrolled women; a protocol page says the approval trials “used 1.75mg for all participants regardless of sex”, though elsewhere it says they enrolled women only.
- Citations that could not be traced, or lead elsewhere. The same article on use in men describes a “phase 2 clinical trial involving 271 men” given 1.75 mg and a journal report of about 55% improving against 25% on placebo; neither was found in this review’s sources, in PubMed or in the trial registry, which is not proof that neither exists. Seven of its eight PubMed numbers belong to unrelated papers, the eighth to a study of melanotan II, and it lists the retracted 2008 trial in women, retitled and not marked as retracted.
- The label re-explained, and contradicted. A protocol page puts the monthly limit partly down to receptor downregulation, a word the label does not use. The article on use in men also says bremelanotide “doesn’t interact with nitrate medications or cause the cardiovascular side effects associated with PDE5 inhibitors” and suits men whose heart conditions rule those drugs out; the label contraindicates it in “uncontrolled hypertension or known cardiovascular disease”.
- Figures with no origin, and a study overlooked. No study, label or calculation is named for the recurring 0.5 and 1 mg starts or the 2 mg top; one protocol page sets doses by body weight on “anecdotal reports and pharmacological logic”, down to the 0.75 mg that did not differ from placebo. Three pages call the combination with a PDE5 inhibitor unstudied; one randomized laboratory crossover gave 7.5 mg by nose with sildenafil 25 mg to 19 men.
The dose is the prescriber’s decision for one patient.
Safety, and who should be most cautious
These figures come from trials of bremelanotide and the Vyleesi label; compounded and online products have not been studied.
In the phase 3 trials (627 women on Vyleesi, 620 on placebo) the most common adverse events were nausea (40.0% against 1.3%), flushing (20.3% against 0.3%), injection-site reactions (13.2% against 8.4%), headache (11.3% against 1.9%) and vomiting (4.8% against 0.2%). Serious adverse reactions were reported in 1.1% against 0.5%. Nausea was most frequent after the first dose (21%) and fell to about 3% after later doses; 8% of women on the drug left the trials because of it.
Blood pressure. The label reports “maximal increases of 6 mmHg in systolic blood pressure (SBP) and 3 mmHg in diastolic blood pressure (DBP) that peaked between 2 to 4 hours post dose”, a fall in heart rate of up to 5 beats a minute, and a return to baseline “usually within 12 hours”. The FDA judged that these rises, at up to 8 doses a month, “are not expected to appreciably increase the risk of cardiovascular disease in the indicated population, which is generally at low cardiovascular risk”; that population is premenopausal women.
Skin darkening. Dark patches on the face, gums or breasts were reported in 1% of women using up to 8 doses a month, more often in women with dark skin; the FDA’s review says reversal was documented in half of the cases during follow-up. They reached 38% after 8 days of daily doses in an uncontrolled study, and 63.3% (against 7.1% on placebo) with three doses a day for 15 days.
Liver. The label reports “a single case of acute hepatitis” in the trials, with “serum transaminases exceeding 40 times the upper limit of normal”, and says “the role of VYLEESI could not definitively be excluded”. The FDA’s review classed it as “possible but not probable” drug-induced liver injury.
Alcohol. A 24-person study of the nasal form found no clinically significant effect on blood levels and no significant drop in blood pressure.
Theory, labelled as theory. People with a history of melanoma or many atypical moles have the most reason for caution, on theory alone: they were not specifically studied, and bremelanotide activates MC1R on pigment cells. For melanotan II, a different molecule, a review says “Four case reports have described melanomas emerging from existing moles”, while “conclusive evidence linking these phenomena is lacking”; no melanoma signal appears in the Vyleesi label, and two-year cancer studies in rats and mice were negative. For men, priapism (a prolonged erection) is a theoretical risk: the FDA’s note on melanotan II lists it among adverse events in case reports, and no case appears in the abstracts of the men’s bremelanotide studies we read, though the clinic series reports “bothersome spontaneous erections” for about 24 hours after injection in 27%.
| Situation | What is known | Basis |
|---|---|---|
| Pregnancy | “may be associated with the potential for fetal harm”; the label advises effective contraception. In dogs, loss of pregnancies rose about 3 to 8-fold, with no no-effect level set | Label; animal studies |
| Breastfeeding | “transferred into breast milk in clinically insignificant amounts” | Label; 10 women, infants not studied |
| Children, and older adults | Safety and effectiveness “have not been established” | Label |
| Men, and women after menopause | No trial studied long-term use in men, or the approved product after menopause | Who the trials enrolled |
| High blood pressure or heart disease | Contraindicated in “uncontrolled hypertension or known cardiovascular disease”; “not recommended in patients at high risk for cardiovascular disease” | Label |
| Melanoma history, or many atypical moles | Not studied | Theory, from MC1R and reports on melanotan II |
| Kidney or liver impairment | Blood levels about 2-fold higher in severe kidney impairment and 1.7-fold in moderate liver impairment; the label says “Use with caution” | Label, measured in people |
| Medicines taken by mouth | It slows stomach emptying. Of 17 oral drugs tested, including birth-control hormones, only naltrexone and indomethacin were judged clinically relevant; the label says to avoid it when naltrexone treats alcohol or opioid addiction | Label |
| GLP-1 medicines | Not studied. Both slow stomach emptying and cause nausea, so the effects could add up | Theory |
| Depression, or psychiatric medicines | Not studied; excluded from the phase 3 trials | Trial exclusion criteria |
Product quality
- The approved product is a manufactured autoinjector with a fixed dose.
- Compounded bremelanotide is prepared by a pharmacy for one patient’s prescription. We found no published data on its quality.
- “Research use only” PT-141. We found no published analysis of the purity, dose accuracy or sterility of PT-141 sold this way in the US; a seller’s own certificate of analysis is not evidence. The one published analysis we found, from Italy, identified melanotan II and bremelanotide in eight samples seized by police. It reported what they were, not how pure or how strong.
- Stability (lab study). Bremelanotide breaks down under oxidation, heat and light. That a product stored or shipped without temperature control loses strength is an inference; nobody has studied it.
What we make of it
This section is our judgment, not a finding.
For premenopausal women with HSDD, the approved product has a real effect in large trials and a small one on average: about a third of a point more than placebo on a desire scale that runs from 1.2 to 6.0, no more satisfying sexual events, and nausea in four of ten. More women on the drug than on placebo counted as responders, by 9 to 23 percentage points depending on the measure. The label’s own test of who is helped is to stop after 8 weeks if there is no improvement.
For men, the hype outruns the evidence. That a drug acting on these brain receptors can produce an erection is plausible, and it was seen in the laboratory. Outside the laboratory, the only published report we found in good standing is one uncontrolled, developer-funded series from a single clinic. For it to count as a treatment there would have to be an at-home randomized trial in good standing, with blood-pressure data. There isn’t one.
For compounded bremelanotide, the trial results were earned by the approved product. That a compounded preparation performs the same way is an assumption no published study has tested; it rests on the pharmacy’s quality and the prescriber’s judgment.
We don’t read the short weight studies, in which three doses a day darkened the skin of 63% of the women, as support for its use for weight loss.
For whom, after what, with what monitoring and when to stop are the Medical Director’s to state.
Peptide care at Rock Creek Wellness
Our peptide care starts with lab tests and a visit with one of our providers. The provider decides whether any peptide suits you, and which one; you don’t choose from a menu. How that care works is set out on our peptide therapy page, along with the other reviews in this library. What Peptide Care costs is on the same page.
So that you can weigh this review knowing our interest: RCW’s providers prescribe some of the peptides reviewed in this library, and RCW earns money from that care.
What would change this review
- Trials with no results yet. A phase 3 trial in Korea (NCT04943068; 193 women; completed in May 2023), a phase 2 trial with tirzepatide for obesity (NCT06565611), a 2006 to 2007 nasal-spray study whose registry entry lists postmenopausal women (NCT00425256), and the pregnancy registry and retrospective study the FDA required.
- What is missing. A randomized at-home trial in men, a trial in women after menopause, and a published analysis of the purity and strength of compounded or online products.
- Status. Vyleesi being discontinued or put on the FDA’s shortage list, or a statement from the Kansas Board of Pharmacy on its copy rule.
Common questions
Is PT-141 FDA-approved?
Bremelanotide is FDA-approved only as Vyleesi, for premenopausal women with acquired, generalized hypoactive sexual desire disorder. Compounded bremelanotide, often sold as PT-141, is not FDA-approved, and the FDA calls the “research use only” products sold online unapproved new drugs.
Does PT-141 work for men?
It has not been shown to outside a laboratory. Tested in people: in short studies run by the developer it produced erections measured on a monitor. Reported in people: one uncontrolled clinic series, with no dose stated. The one large at-home trial is under an Expression of Concern, and no trial has measured desire in men. Vyleesi is not indicated in men; compounded bremelanotide is not FDA-approved for any use.
How quickly does it work, and how long does it last?
Blood levels peak about an hour after an injection under the skin. How long the effect lasts is unknown: in one small study women reported more desire for up to 24 hours, and the claim of 72 hours has no data behind it.
How often is it taken?
In the trials of the approved product it was used as needed, not on a schedule: a median of 10 injections in 24 weeks. The Vyleesi label says not to take more than one dose in 24 hours and does not recommend more than 8 a month. Most pages found repeat those two limits; three state weekly or 48-hour frequencies that come to more, which is practice no trial set. How often one patient uses it is the prescriber’s decision.
Can a doctor prescribe PT-141?
Vyleesi, the FDA-approved product, is a prescription medicine. Compounded bremelanotide is dispensed only on a prescription written for one patient, and it is not FDA-approved. Federal law and Kansas’s rule for sterile preparations limit when a pharmacy may compound what is essentially a copy of Vyleesi.
Sources
Show all 43 sourcesHide sources
- VYLEESI (bremelanotide injection), prescribing information, SPL version 2. Cosette Pharmaceuticals / DailyMed (NLM), 2026.
- NDA 210557 Multi-Disciplinary Review and Evaluation: Vyleesi (bremelanotide). FDA CDER, 2019.
- Vyleesi (NDA 210557), Drugs@FDA record. FDA, read through openFDA, 2026.
- 21 U.S.C. 353a. U.S. Code, read at Cornell LII, 2026.
- Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A. FDA, 2018.
- Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act. FDA, 2025.
- K.A.R. 68-13-4, Sterile preparations. Kansas Secretary of State, 2018.
- K.A.R. 68-13-2, Definitions. Kansas Secretary of State, 2018.
- Board of Pharmacy, Reports & Guidance Docs. Kansas Board of Pharmacy, 2026.
- Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (notice of availability, 91 FR 68526, FR Doc. 2026-22192). Federal Register, 2026.
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. HHS, 2026.
- FDA warning letters, all August 24, 2026: Peptide Partners LLC 735063; Peak Performance Peptides 735127; Royal Peptides LLC 734884; TXP Innovations LLC dba Tex Peptides 735067; NuScience Peptides LLC 733652. FDA, 2026.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. FDA, 2026.
- World Anti-Doping Code International Standard: Prohibited List 2026. WADA, 2025.
- The Prohibited List: the 2027 List. WADA, 2026.
- PubChem compound records: Bremelanotide, CID 9941379 and Melanotan II, CID 92432. NCBI, 2026.
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology, 2019.
- Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstetrics & Gynecology, 2019.
- Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial. Women’s Health (London), 2016.
- Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants. Clinical Therapeutics, 2017.
- Safety Profile of Bremelanotide Across the Clinical Development Program. Journal of Women’s Health, 2022.
- Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. Journal of Women’s Health, 2022.
- Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire disorder. Journal of Clinical Investigation, 2022.
- Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials. Diabetes, Obesity and Metabolism, 2022.
- Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. International Journal of Impotence Research, 2004.
- Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. International Journal of Impotence Research, 2004.
- Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. Urology, 2005.
- An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. Journal of Sexual Medicine, 2006.
- Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. Journal of Urology, 2008. Expression of Concern, Journal of Urology, 2023.
- RETRACTED: Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder. Journal of Sexual Medicine, 2008 (retracted).
- Re-Analyzing Phase III Bremelanotide Trials for “Hypoactive Sexual Desire Disorder” in Women. Journal of Sex Research, 2021.
- Failure of a Meta-analysis: A Commentary on Glen Spielmans’s “Re-Analyzing Phase III Bremelanotide Trials”. Journal of Sex Research, 2021.
- Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder. Journal of Sex Research, 2024.
- Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. PNAS, 2004.
- The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS Spectrums, 2022.
- Female Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female hypoactive sexual desire disorder. Neuropharmacology, 2025.
- Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics. Journal of Pharmaceutical and Biomedical Analysis, 2020.
- LC-HRMS characterization of the skin pigmentation and sexual enhancers melanotan II and bremelanotide sold on the black market of performance and image enhancing drugs. Drug Testing and Analysis, 2021.
- Comprehensive characterization of bremelanotide acetate and its degradants by LC-HRMS/MS and predicting epimerization through computational modelling. Analytical Methods, 2026.
- Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides, 2006.
- Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. International Journal of Dermatology, 2017.
- ClinicalTrials.gov records: NCT00425256, NCT04943068, NCT06565611. U.S. National Library of Medicine, 2026.
- (235) Use of Bremelanotide (Vyleesi) in Men with Sexual Dysfunctions. The Journal of Sexual Medicine, 2024.
